Intelligence Feed event · Policy · 2026-09-03

    NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer

    Question

    NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer

    Direct answer

    Revolution Medicines announced that the New England Journal of Medicine has published Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The peer-reviewed data demonstrated a 42% objective response rate and a median overall survival of 16.0 months. The publication strengthens clinical validation for targeted RAS(ON) inhibitors in solid tumors where treatment options post-chemotherapy remain limited.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-03
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer”, revision 1, evidence through 2026-09-03. https://marketontology.com/market-events/2026-09-03/nejm-publishes-revolution-medicines-phase-1-2-data-for-daraxonrasib-in-lung-canc-ddab7c

    POLICY
    NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer
    Revolution Medicines announced that the New England Journal of Medicine has published Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The peer-reviewed data demonstrated a 42% objective response rate and a median overall survival of 16.0 months. The publication strengthens clinical validation for targeted RAS(ON) inhibitors in solid tumors where treatment options post-chemotherapy remain limited.
    RVMD
    Impact
    71
    SEP 3
    SIG
    90%
    RVMD
    NEJM Publishes Revolution Medicines Phase 1/2 Data for Daraxonrasib in Lung Cancer
    Revolution Medicines announced that the New England Journal of Medicine has published Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The peer-reviewed data demonstrated a 42% objective response rate and a median overall survival of 16.0 months. The publication strengthens clinical validation for targeted RAS(ON) inhibitors in solid tumors where treatment options post-chemotherapy remain limited.
    → Peer-reviewed publication of 42% response rates and 16.0-month median overall survival de-risks late-stage development of daraxonrasib, supporting oncology pipeline equity valuation for RVMD.
    Impact
    Revolution Medicines announced that the New England Journal of Medicine has published Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) targeting previously treated RAS mutant non-small cell lung cancer (NSCLC). The peer-reviewed data demonstrated a 42% objective response rate and a median overall survival of 16.0 months. The publication strengthens clinical validation for targeted RAS(ON) inhibitors in solid tumors where treatment options post-chemotherapy remain limited.
    Affected
    RVMD
    Transmission
    Peer-reviewed publication of 42% response rates and 16.0-month median overall survival de-risks late-stage development of daraxonrasib, supporting oncology pipeline equity valuation for RVMD.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RVMDclinical asset de-risking and pipeline revaluationUp1-4wNEJM published Phase 1/2 data showing 42% ORR and 16.0 months median OS for daraxonrasib.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month